Core Viewpoint - The company, Huaren Health, announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received a drug registration acceptance notice for Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration of China, indicating the product has entered the registration review phase [1] Group 1 - The drug is a novel potassium ion competitive acid blocker used for treating reflux esophagitis and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The acceptance notice signifies the beginning of the registration review process, but the completion time, approval results, and specific sales situation post-approval remain uncertain [1] - The company stated that this development will not have a significant impact on its short-term performance [1]
华人健康：全资子公司收到富马酸伏诺拉生片药品注册受理通知书